Phenotyping patients with chronic cough: Evaluating the ability to predict the response to anti-inflammatory therapy

Sadeghi, Mahboobeh Haji; Wright, Caroline E.; Hart, Simon; Crooks, Michael; Morice, Alyn

Abstract

© 2017 Background: Whether the fraction of exhaled nitric oxide (FeNO) measurement can predict the response to anti-inflammatory treatment in chronic cough is unknown. Objective: To explore whether the effectiveness of treatment with 10 mg of montelukast or 20 mg of prednisolone in patients with chronic cough is predicted by FeNO level. Methods: In this randomized, open-label, controlled pilot study conducted in the Clinical Trial Unit in Castle Hospital in the United Kingdom, 50 nonsmoking patients with a cough that lasted more than 8 weeks were sequentially enrolled in the study. Thirty patients with high FeNO levels (≥30 ppb) were randomized in a 1:1 ratio to receive 10 mg of montelukast or 20 mg of prednisolone for 2 weeks followed by 10 mg of montelukast for 2 weeks. Twenty patients with a low FeNO level (≤20 ppb) received 10 mg of montelukast. The primary objective was to determine the effectiveness of treatment on 24-hour cough counts. Results: The 24-hour cough counts decreased in both groups by approximately 50% (P

Citation

Sadeghi, M. H., Wright, C. E., Hart, S., Crooks, M., & Morice, A. (2018). Phenotyping patients with chronic cough: Evaluating the ability to predict the response to anti-inflammatory therapy. Annals of Allergy, Asthma and Immunology, 120(3), 285-291. https://doi.org/10.1016/j.anai.2017.12.004

• Journal Article Type: Article
• Acceptance Date: Dec 11, 2017
• Online Publication Date: Mar 1, 2018
• Publication Date: 2018-03
• Deposit Date: May 10, 2022
• Journal: Annals of Allergy, Asthma and Immunology
• Print ISSN: 1081-1206
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 120
• Issue: 3
• Pages: 285-291
• DOI: https://doi.org/10.1016/j.anai.2017.12.004
• Public URL: https://hull-repository.worktribe.com/output/3565502